Crohn´s Disease Clinical Trial
— ONManCDOfficial title:
Soft Ostheopathic Techniques Improve the Quality of Life in Patients With Crohn's Disease. A Randomized Controlled Trial.
Verified date | July 2016 |
Source | University of Valencia |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ethics Committee |
Study type | Interventional |
Crohn's disease (CD) is an inflammatory bowel disease with a high prevalence. Its etiology is unknown and is considered a multifactorial disease. It is known that the existence of a genetic factor, industrialization and development of the country and environmental factors have great influence on the appearance of intestinal pathology (the Val; Buderus; Molodecky). CD is a chronic inflammatory bowel disease localized throughout the course of the digestive tract (oral-anal). The aim of this study is to evaluate the effect of a treatment program combining technical nonmanipulative appropriate in affected patients (CD) to increase the overall quality of life and related EC, lower abdominal pain direct and indirect osteopathic soft, observe the sense of change after treatment, and psychological aspects.
Status | Completed |
Enrollment | 33 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients diagnosed with active CD of at least one year of evolution, aged between 18 and 65, with a presence of abdominal pain, receiving conservative or surgical treatment (after 6 months after surgery and absence of diverting ileostomy) were included. Once they expressed their interest in taking part of the study, potential participants underwent an examination by a specialist of the association to confirm the diagnosis of CD. Exclusion Criteria: - Conversely, patients with non-specific inflammatory bowel, abdominal tenderness, infection, ischaemia, physical damage, or specific immunologic sensitivity or pregnancy be excluded of this study were discarded for the study. |
Allocation: Non-Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Faculty of Physiotherapy | Valencia |
Lead Sponsor | Collaborator |
---|---|
University of Valencia |
Spain,
Florance BM, Frin G, Dainese R, Nébot-Vivinus MH, Marine Barjoan E, Marjoux S, Laurens JP, Payrouse JL, Hébuterne X, Piche T. Osteopathy improves the severity of irritable bowel syndrome: a pilot randomized sham-controlled study. Eur J Gastroenterol Hepat — View Citation
Piche T, Pishvaie D, Tirouvaziam D, Filippi J, Dainese R, Tonohouhan M, DeGalleani L, Nébot-Vivinus MH, Payrouse JL, Hébuterne X. Osteopathy decreases the severity of IBS-like symptoms associated with Crohn's disease in patients in remission. Eur J Gastro — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain. | by a horizontal line 10 cm in length (0 = no pain to 10 = maximum pain). | 4 weeks | No |
Secondary | Global Quality Of Life | Functional Assessment of Cancer Therapy- General (VersiĆ³n 4- FACT-G) | 4 weeks | No |
Secondary | Quality Of Life in CD | Inflammatory Bowel Disease Quality Of Life-32 (IBDQ-32) | 4 weeks | No |
Secondary | Index of Crohn's disease activity | By the Harvey-Bradshaw Index (HBI) | 4 weeks | No |
Secondary | Existence of anxiety and depression | by Goldberg Anxiety and Depression Scale | 4 weeks | No |
Secondary | Anxiety and Depression | Hospital Anxiety and Depression Scale (HADS) | 4 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01102855 -
Endomicroscopy and Crohn´s Disease
|
N/A | |
Completed |
NCT01279577 -
Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease
|
Phase 2 | |
Completed |
NCT01086553 -
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
|
Phase 3 | |
Completed |
NCT01289366 -
Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD)
|
N/A | |
Recruiting |
NCT06006039 -
The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
|
||
Recruiting |
NCT04022083 -
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
|
||
Completed |
NCT03890445 -
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
|
||
Completed |
NCT01564823 -
Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease
|
Phase 3 | |
Completed |
NCT01768858 -
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
|
||
Completed |
NCT01417702 -
Endoscopy for Assessment of Mucosal Healing in IBD
|
||
Completed |
NCT01417715 -
Endomicroscopy for Assessment of Mucosal Healing
|
||
Terminated |
NCT00862121 -
A Study With Pentasa in Patients With Active Crohn's Disease
|
Phase 3 |